Flow Cytometry Global Market Report 2021: COVID-19 Growth And Change To 2030

Flow Cytometry Global Market Report 2021: COVID-19 Growth And Change To 2030

  • September 2021 •
  • 175 pages •
  • Report ID: 6151579 •
  • Format: PDF
Major players in the flow cytometry market are Beckman Coulter, Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher and Luminex.

The global flow cytometry market is expected to grow from $4.11 billion in 2020 to $4.52 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.07 billion in 2025 at a CAGR of 7.6%.

The flow cytometry market consists of sales of flow cytometry instruments, software and chemicals and related services.Flow cytometry is used to analyze characteristics of a biological cell such as cell size, cell count and cell complexity using laser optics.

In the flow cytometry technique, cells are added to a fluid medium which is then passed through a pulsating laser beam. The cell then scatters the beam in different directions towards receptors that capture the light and translate it to data displayed on a monitor.

The flow cytometry market covered in this report is segmented by type into instruments, reagents & consumables, software, accessories, services. It is also segmented by technology into cell-based, bead-based; by end user into hospitals and clinics, academia and research institutes, pharmaceutical and biotechnology companies, other end users and by application into oncology, drug discovery, disease diagnosis, stem cell therapy, organ transplantation, hematology.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The availability of cheaper and better substitutes for flow cytometry is a major restrain on the flow cytometry market.These substitutes include ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay.

While flow cytometry, ELISA and radioimmunoassay are all methods that help in HIV diagnosis by detecting “problem cells” in a group of cells, ELISA and radioimmunoassay are cheaper and easier methods than flow cytometry.In ELISA, colour changes in reagents are used to detect problematic cells.

While in radioimmunoassay, cells are given certain radioactive markers which are used to detect problematic cells.Both ELISA and radioimmunoassay can be implemented using cheap, traditional laboratory equipment and reagents with a higher throughput rate.

However, flow cytometry involves high setup costs and costs of interpreting data along with a very low throughput.

High-throughput flow cytometry is an emerging trend in the flow cytometry market.This is due to high speed of cell parameter processing and capability to analyze several heterogeneous cell groups at once, using this technique.

Traditional cytometry methods are very slow, especially when several cells need to be tested within a day.Using high-throughput flow cytometry methods such as fluorescence-activated cell-sorting (FACS), multiple cells can be allotted fluorescent markers which can be used to analyze their parameters in quick time.

Examples of companies that offer high-throughput flow cytometry solutions include AstraZeneca and Novartis.

In February 2019, Danaher acquired the biopharma business of GE Life Sciences for $21.4 billion. This acquisition will help Danaher to improve its existing bioprocessing capabilities. The biopharma division of GE Life Sciences is involved in the development and production of biologic drugs, vaccines and cell therapies. It develops products and solutions that facilitate research into fundamental cell and protein biology. GE Life Sciences is a division of GE Healthcare, which was founded in 1994 and has its headquarters in Illinois, the USA.

The increasing number of HIV cases globally is an important driver for the flow cytometry market.This is because the flow cytometry technique has its direct application in HIV diagnosis.

Flow cytometry uses light scattering to determine the identity of cells.These cells are given certain markers called CDs (clusters of differentiation), based on the type of scattering.

For the HIV virus cell, the clusters of differentiation is called CD4, and based on the number of CD4s in a medium, flow cytometry can be used to diagnose HIV. As the global HIV population continues to grow, the demand for diagnosis techniques such as flow cytometry is also increasing.

The US FDA’s code of federal regulations (CFR) includes regulations related to a flow cytometry device called the automated differential cell counter (ADCC).An ADCC is a device used in the study of blood cells, mainly for the detection of faulty blood cells and low blood cell counts.

This device comes under the purview of the class 2 special controls guidance document which outlines requirements such as the methods for accurate and precise reporting of results, the statistical linearity conditions of graph-based cytometry results and the types of specimens to be used.Flow cytometry device manufacturers must conform to these guidelines, which address the specific health risks associated with ADCC devices.

Hence, this is expected to maintain a vigil on flow cytometry companies involved in manufacturing ADCC.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.